Key facts
- This page summarizes Ali Zarrin's Form 3 filing for TRex Bio, Inc..
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 08 Oct 2026, 21:43.
Ali Zarrin - 08 Oct 2026 Form 3 Insider Report for TRex Bio, Inc.
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 08 Oct 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Brandon Hants, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Ali Zarrin filed Form 3 for TRex Bio, Inc. on 08 Oct 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002154774
Primary reporting owner
Zarrin Ali
- Relationship
- Chief Scientific Officer
- Address
- C/O TREX BIO, INC., 269 EAST GRAND AVENUE, SUITE 300, SOUTH SAN FRANCISCO
- Signature
- /s/ Brandon Hants, Attorney-in-Fact
- Signature date
- 08 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,111
- Date
- 08 Oct 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 08 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,264
- Exercise price
- $1.09
- Footnotes
- F1
No ticker
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 08 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,913
- Exercise price
- $1.24
- Footnotes
- F2
No ticker
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 08 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 186,015
- Exercise price
- $1.24
- Footnotes
- F3
No ticker
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 08 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 66,889
- Exercise price
- $1.28
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The option had a vesting start date of May 25, 2022. 25% of the options vested on May, 25, 2023, and vests as to the remaining shares in equal monthly installments over 36 months, subject to continued service through the applicable vesting dates.
Footnote F2
The option had a vesting start date of April 1, 2025 and vests in equal monthly installments over 48 months, subject to continued service through the applicable vesting dates.
Footnote F3
The option had a vesting start date of August 13, 2025 and vests in equal monthly installments over 48 months, subject to continued service through the applicable vesting dates.
Footnote F4
The option had a vesting start date of February 19, 2026 and vests in equal monthly installments over 48 months, subject to continued service through the applicable vesting dates.
SEC remarks
Exhibit List: Exhibit 24 - Power of Attorney